Anti-CD130/IL-6RB Antibody, clone 2I13 ZooMAb^® Rabbit Monoclonal

Quality Control Testing

Evaluated by Western Blotting in rat liver tissue lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected GP130/CD130 in rat liver tissue lysate.

Tested Applications

Affinity Binding Assay: A representative lot of this antibody bound with CD130/IL-6RB peptide with at least ten thousand-fold (10,000X) higher affinity than with non-specific control peptide.

Immunocytochemistry Analysis: A 1:100 Dilution from a representative lot detected CD130/IL-6RB in U937 cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 2I13 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects GP130/CD130. It targets an epitope within 23 amino acids from the C-terminal half.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Interleukin-6 receptor subunit beta (UniProt: P40189; also known as IL-6 receptor subunit beta; IL-6R subunit beta, IL-6R-beta, IL-6RB, CDw130, Interleukin-6 signal transducer, Membrane glycoprotein 130 (gp130), Oncostatin-M receptor subunit alpha, CD130) is encoded by the IL6ST gene (Gene ID: 3572) in human. CD130 is a transmembrane glycoprotein that serves as a signal-transducing subunit for the type I cytokine receptor family. CD130 is composed of five fibronectin type-III domains and one immunoglobulin-like domain, with a hallmark WSXWS amino acid motif that ensures proper folding and ligand binding. It interacts with Janus kinases (JAKs) to elicit intracellular signaling upon binding to cytokines such as interleukin-6 (IL-6), leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), and others. CD130 is expressed across diverse tissues, including hematopoietic stem cells, endothelial progenitors, and various immune cells. CD130 is central to cytokine signaling pathways, particularly the IL-6 signaling axis. Upon binding with cytokine-specific receptors, CD130 facilitates the assembly of receptor complexes that activate downstream signaling cascades, including the JAK/STAT pathway and MAPK/ERK pathway. These pathways regulate numerous cellular processes, such as inflammation, apoptosis, cell survival, and differentiation. CD130 also plays a critical role in immune responses by promoting the differentiation of Th17 cells and enhancing B-cell immunoglobulin production. Additionally, CD130 contributes to metabolic regulation and bone remodeling by modulating osteoclast function. Dysregulation of CD130-mediated signaling has been implicated in various pathological conditions, including autoimmune diseases (e.g., rheumatoid arthritis), inflammatory disorders, and cancers. Elevated serum levels of IL-6 and CD130 activity are often observed in chronic inflammatory diseases and are associated with disease severity. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

KLH-conjugated linear peptide corresponding to 23 amino acids from the C-terminal half of human GP130/CD130.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany